The economic case for scaling up health research and development: Lessons from the COVID-19 pandemic
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2321978121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Daniel Tortorice und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Economics and Accounting, College of the Holy Cross, Worcester, MA 01610. Hauptthemen laut MEDLINE: COVID-19, Pandemics. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, International Vaccine Institute, The Davos Alzheimer's Collaborative.
Abstract (Originalsprache)
In response to the COVID-19 pandemic, governments directly funded vaccine research and development (R&D), quickly leading to multiple effective vaccines and resulting in enormous health and economic benefits to society. We develop a simple economic model showing this feat could potentially be repeated for other health challenges. Based on inputs from the economic and medical literatures, the model yields estimates of optimal R&D spending on treatments and vaccines for known diseases. Taking a global and societal perspective, we estimate the social benefits of such spending and a corresponding rate of return. Applications to Streptococcus A vaccines and Alzheimer’s disease treatments demonstrate the potential of enhanced research and development funding to unlock massive global health and health-related benefits. We estimate that these benefits range from 2 to 60 trillion (2020 US$) and that the corresponding rates of return on R&D spending range from 12% to 23% per year for 30 y. We discuss the current shortfall in R&D spending and public policies that can move current funding closer to the optimal level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Economics and Accounting, College of the Holy Cross, Worcester, MA 01610.
- Fondazione Biotecnopolo di Siena, Siena 53100, Italy.
- Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA 02115.
ORCID-Profile: Rino Rappuoli
Förderung
- Wellcome Trust
- International Vaccine Institute
- The Davos Alzheimer's Collaborative
- The Davos Alzheimer's Collaborative
Zitieren
APA
Tortorice, D., Rappuoli, R., & Bloom, D. E. (2024). The economic case for scaling up health research and development: Lessons from the COVID-19 pandemic. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2321978121
Vancouver
Tortorice D, Rappuoli R, Bloom DE. The economic case for scaling up health research and development: Lessons from the COVID-19 pandemic. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2321978121
BibTeX
@article{Tortorice2024,
author = {Tortorice, Daniel and Rappuoli, Rino and Bloom, David E},
title = {The economic case for scaling up health research and development: Lessons from the COVID-19 pandemic},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2321978121}
}
EUVIMED